There is compelling evidence for a role for two types of chemical, tobacco specific nitrosamines and heterocyclic amines, in the induction of pancreatic ductal adenocarcinoma in humans. There are animal models for this form of cancer involving tobacco specific nitrosamines and other experimental evidence implicating heterocyclic amines. We propose to examine the actions of a representative amine (2-amino-1-methyl-6- phenylimidazo [4,5-b] pyridine (PhlP) and nitrosamine (4- (methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)) and the carcinogenic nitrosamine MIP (N-nitrosomethyl (2-oxopropyl)amine) in pancreatic duct epithelial cells (DEC) from humans and from the appropriate rodent species and strains. We will concentrate on the metabolic activation of these chemicals focussing on the enzyme(s) that are involved in their metabolism.
Our aim here is to determine those enzymes that may predispose humans to the pancreatrophic actions of environmental chemicals and to attempt to define groups who are at risk for pancreas cancer induction. We will determine the profile of metabolizing enzymes in both human and rodent DEC, focussing on those enzymes that are known to be involved in the activation of carcinogens. Having established this profile we will examine the ability of specific enzymes, mostly P450 isoforms, to metabolize MIO, NNAL and PhlP using the profile of metabolites and the ability to induce mutations. The ability of these carcinogens, activated by enzymes that are identified in the earlier aims, to neoplastically transform DEC will be measured. Lastly we will examine the capacity of DEC to repair different forms of DNA damage. A crucial factor in determining susceptibility might be the ability of DEC to repair DNA damage caused by the putative carcinogens. Our understanding of chemically induced pathological conditions is seriously hindered by a lack of knowledge of the ability of these cells to metabolize chemicals and to repair the genetic consequences of this activation. This proposal seeks to address some of these concerns and issues.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA072712-03
Application #
6103311
Study Section
Project Start
1999-03-25
Project End
2003-01-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Nebraska Medical Center
Department
Type
DUNS #
City
Omaha
State
NE
Country
United States
Zip Code
68198
Chan, June M; Gong, Zhihong; Holly, Elizabeth A et al. (2013) Dietary patterns and risk of pancreatic cancer in a large population-based case-control study in the San Francisco Bay Area. Nutr Cancer 65:157-64
Mutolo, Michael J; Morris, Kirsten J; Leir, Shih-Hsing et al. (2012) Tumor suppression by collagen XV is independent of the restin domain. Matrix Biol 31:285-9
Pour, Parviz M (2012) A novel tissue for islet transplantation in diabetics. Pancreatology 12:57-60
Sherman, Simon; Shats, Oleg; Ketcham, Marsha A et al. (2011) PCCR: Pancreatic Cancer Collaborative Registry. Cancer Inform 10:83-91
Chan, June M; Wang, Furong; Holly, Elizabeth A (2009) Sweets, sweetened beverages, and risk of pancreatic cancer in a large population-based case-control study. Cancer Causes Control 20:835-46
Moniaux, Nicolas; Nemos, Christophe; Deb, Shonali et al. (2009) The human RNA polymerase II-associated factor 1 (hPaf1): a new regulator of cell-cycle progression. PLoS One 4:e7077
Mimeault, M; Hauke, R; Batra, S K (2008) Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83:673-91
Hennig, R; Osman, T; Esposito, I et al. (2008) BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation. Br J Cancer 99:1064-73
Davda, Jasmine P; Jain, Maneesh; Batra, Surinder K et al. (2008) A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 8:401-13
Hennig, Rene; Kehl, Timo; Noor, Seema et al. (2007) 15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. Neoplasia 9:917-26

Showing the most recent 10 out of 108 publications